This point also provides a rationale for exploring MAPK kinase (MEK) inhibitors in the treatment of low-grade serous ovarian cancer, such as selumetinib, trametinib or dabrafenib, which are MEK1 and MEK2 inhibitors (MEKi) that indirectly inhibit the BRAF and KRAS pathways [21]. Here, MAP2K1 is linked to ovarian serous adenocarcinoma.